Researchers at Boston University College of Health & Rehabilitation Sciences: Sargent College have identified a combinatorial therapeutic approach that has proven effective in treating muscular dystrophy in a mouse model.
The findings, published in Human Molecular Genetics, represent a paradigm shift for the treatment of muscular dystrophy as well as a host of other disabling and devastating muscle diseases.
The study was led by Mahasweta Girgenrath, PhD, assistant professor and director of the Muscle Disorders and Regenerative Biology Laboratory at BU Sargent College’s Department of Health Sciences. Boston University (BU) researchers and postdoctoral fellows Jenny Yamauchi, Ajay Kumar, Lina Duarte, and Thomas Mehuron were collaborators on this study.
Muscular Dystrophy type 1A (MDC1A) is the second most common form of congenital muscular dystrophy. Patients with this disease have poor muscle tone at birth, extremely compromised neuromuscular function, and are rarely able to walk independently. Most patients with MDC1A succumb to a premature death due to either respiratory complications or failure to thrive. Although significant strides have been made towards understanding the molecular and biochemical mechanisms underlying MDC1A, there remains no effective therapy in place to combat this lethal disease.
The research team, led by Girgenrath, hypothesized that the complex pathology seen in MDC1A may be the result of dysregulation of multiple cellular functions and processes, meaning that strategies which simultaneously target several of those mechanisms might lead to a reduction of symptoms.
“Very few studies have utilized the power of combinatorial therapy in the context of muscular dystrophy.” said Professor Girgenrath, the study’s corresponding author. “While most MD treatments are single-target therapies, we’re delving into combinations of different therapies to target multiple pathways.”
The research team studied the outcome of combining the following single mode treatments: increasing regeneration, by overexpressing muscle specific insulin like growth factor-1, IGF-1 and preventing cell death, by inhibiting the expression of Bax, a pro-apoptotic protein. In addition, to test the translational potential of this combination therapy, the researchers systemically treated Bax deficient dystrophic mice with recombinant human IGF-1 (IPLEX TM, manufactured by Insmed Inc).
By combining these two therapies, researchers found that in addition to increased body and muscle weight, mice showed enhanced locomotory capacities and remarkable improvement in muscle pathology. The most impressive outcome was the significant resolution of inflammation and fibrosis, not seen with single mode therapies. The research team concluded that the use of this combination therapy is an effective treatment for MDC1A, highlighting a compelling argument that a combinatorial approach has a synergistic benefit and could have the potential of treating patients with congenital muscular dystrophy.
The Latest Bing News on:
Novel Therapy to Treat Muscular Dystrophy
- Experts develop immune-enhancing therapies to target tuberculosison April 26, 2024 at 3:10 pm
Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to target tuberculosis, with hopes that they could tackle even the ...
- U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia Bon April 26, 2024 at 7:45 am
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the ...
- 14 recent scientific breakthroughson April 24, 2024 at 8:40 am
T cells are integral in the immune system but can become "dysfunctional inside tumors." "The approval of Amtagvi represents the culmination of scientific and clinical research efforts leading to a ...
- Researchers uncover SNUPN gene responsible for a new muscular disorderon April 24, 2024 at 8:03 am
A study, published in Nature Communications, sheds light on a newly identified subtype of muscular dystrophy, revealing an unsuspected role of SNUPN gene in muscle cell function.
- Koç University Researchers Uncover SNUPN Gene Responsible for a New Muscular Disorderon April 23, 2024 at 11:53 pm
Koç University researchers have uncovered a new muscular disorder linked to SNUPN deficiency. Published in Nature Communications, this groundbreaking ...
- Glucocorticoid use can aid breathing ability in Duchenne adults: Studyon April 23, 2024 at 8:28 am
Glucocorticoid use was seen to help maintain breathing ability and arm function in adults in the late stages of Duchenne muscular dystrophy.
- My son's smile gives me hope for Duchenne muscular dystrophy. A new law could help otherson April 23, 2024 at 5:01 am
Opinion: Newborn testing can give families a head start on giving a child with the degenerative muscular disease a shot at the best outcome in life.
- MEDCARE WOMEN & CHILDREN HOSPITAL leads the way in advanced Gene Therapy with 100 successful Spinal Muscular Atrophy Infusionson April 23, 2024 at 3:38 am
Medcare Women & Children Hospital (MWCH) in Dubai has announced reaching a milestone record of administering 100 gene therapy ...
- 2-year EDG-5506 treatment helps preserve motor function in BMDon April 18, 2024 at 8:54 am
Oral treatment with EDG-5506 continued to stabilize muscle function after two years in men with Becker MD taking part in a Phase 1 trial.
- Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Studyon April 18, 2024 at 4:29 am
First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide- - BB-301 facilitated improvements ...
The Latest Google Headlines on:
Novel Therapy to Treat Muscular Dystrophy
[google_news title=”” keyword=”Novel Therapy to Treat Muscular Dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Muscular dystrophy
- These 15 One-of-a-Kind Watches Won’t Appear at the OnlyWatch Auction. We Asked the Brands Why.on April 26, 2024 at 9:00 am
We asked 15 brands why their unique timepieces for OnlyWatch will not appear at the rescheduled auction in Geneva next month, and what the fate of those watches might be.
- Patients With DMD Receiving Eteplirsen Show Prolonged Survival, Study Findson April 25, 2024 at 2:03 pm
The study provides evidence of survival benefits among patients with Duchenne muscular dystrophy (DMD) receiving eteplirsen compared with the natural history of the condition.
- Muscular Dystrophy UK Earns PIF TICK Accreditationon April 25, 2024 at 7:48 am
Muscular Dystrophy UK, the leading charity for more than 110,000 children and adults in the UK living with one of over 60 muscle wasting and weakening ...
- DeWine: Ohio first state in the nation to screen newborn babies for Duchenne Muscular Dystrophyon April 24, 2024 at 9:00 pm
Ohio Gov. Mike DeWine on Monday announced that Ohio will become the first state in the nation to begin screening all newborn babies for Duchenne Muscular Dystrophy. The provision was included in HR 33 ...
- Researchers uncover SNUPN gene responsible for a new muscular disorderon April 24, 2024 at 8:03 am
A study, published in Nature Communications, sheds light on a newly identified subtype of muscular dystrophy, revealing an unsuspected role of SNUPN gene in muscle cell function.
- Gov. DeWine announces Ohio will be first state to screen newborns for DMDon April 24, 2024 at 7:23 am
Gov. Mike DeWine announced Tuesday that the state of Ohio will become the first in the United States to screen all newborn babies for Duchenne muscular dystrophy.
- Ohio sets the trend in screening newborns for rare disease. What to know about DMDon April 24, 2024 at 3:58 am
Ohio Gov. Mike DeWine announced the state will be the first in the nation to screen newborns for the rare disease Duchenne Muscular Dystrophy.
- Edgewise gets EU orphan drug status for muscular dystrophy drugon April 23, 2024 at 7:29 am
Edgewise Therapeutics (EWTX) has received orphan drug designation from EU regulators for sevasemten in the treatment of Becker and Duchenne muscular dystrophies. Read more here.
- Duchenne UK and Parent Project Muscular Dystrophy Award $500,000 to Evaluate Safety and Tolerability of Muscle Progenitor Cells in Phase 1 Trialon April 23, 2024 at 7:01 am
Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization, and the UK charity Duchenne UK, two leading organizations dedicated to ending Duchenne muscular dystrophy (Duchenne), are excited ...
- My son's smile gives me hope for Duchenne muscular dystrophy. A new law could help otherson April 23, 2024 at 5:01 am
Opinion: Newborn testing can give families a head start on giving a child with the degenerative muscular disease a shot at the best outcome in life.
The Latest Google Headlines on:
Muscular dystrophy
[google_news title=”” keyword=”muscular dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]